Arbutus Biopharma Corp (ABUS) Aandeelprys en nuus

TuisABUS • NASDAQ

Arbutus Biopharma Corp

$4,26

16 Mrt., 08:20:34 GMT-4 · USD · NASDAQ · Vrywaring

AandeelVSA-gelyste effekHoofkantoor in VSA

Vorige sluiting

$4,26

Jaarwisseling

$2,71 - $5,10

Markkapitalisasie

819,30 m USD

Gemiddelde volume

2,67 m

P/V-verhouding

Dividend-opbrengs

Primêre beurs

NASDAQ

Marknuus

GlobeNewswire

17 minute gelede

JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute

New to The Street Broadcasts Episode Featuring FreeCast (NASDAQ:CAST), KLED.AI, PetVivo (OTCQB:PETV), EmpowerLit, and BlackBarn NYC on Bloomberg Television - March 21 at 6:30 PM EST

Quipt Home Medical (NASDAQ: QIPT) delists common shares via Form 25

Trump has 15 days to end the Iran war or markets face a brutal April repricing — from oil to the S&P 500

Severe oil shock could drag S&P 500 down to 5,400, Goldman warns

Acadia Pharmaceuticals Rings the Opening Bell

ACAD

0,00%

Meer oor

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

HUB

William H. Collier

Gestig

2007

Hoofkwartier

Warminster Township, Pennsilvanië
Verenigde State van Amerika

Webwerf

arbutusbio.com

Werknemers